News | December 09, 2024
Suven to acquire 56% stake in ADC specialist NJ Bio for US$64.4 million
This acquisition positions Suven as a key player in one of the fastest growing segments of the Pharma CDMO landscape
This acquisition positions Suven as a key player in one of the fastest growing segments of the Pharma CDMO landscape
In the near term, the company targets a 42% reduction in absolute Scope 1 and 2 emissions and Scope 3 emissions by FY2030
EBITDA for the quarter is Rs. 21.6 crore as against Rs. 18.1 crore in Q2 FY24
Donation drive in São Paulo aims to support 250 young women’s health and environmental responsibility
Real-world and long-term extension data, including updated results from post-launch evaluation of REMS Program, bolster growing body of evidence supporting the efficacy and safety profile of CAMZYOS
Combined capabilities to drive novel healthcare applications presented at MEDICA 2024
Commercial license to Synaffix technologies follows a series of successful initial preclinical proof of concept studies
The partnership emphasises the introduction of renewable, bio-based materials into existing plastic applications to help reduce fossil resource dependency
Strengthening focus in Alzheimer's disease and neuroscience pipeline
The workshop aimed to equip medicos with the necessary skills & knowledge to leverage AI's transformative power
Subscribe To Our Newsletter & Stay Updated
